Apo-Desvenlafaxine Use In Pregnancy & Lactation

The safety of desvenlafaxine during human pregnancy has not been established. Taking APO-DESVENLAFAXINE in mid to late pregnancy may increase the risk for preeclampsia (high blood pressure and protein in the urine) and taking it near delivery may increase the risk of heavy bleeding after giving birth. Desvenlafaxine is excreted in human milk. Tell the doctor immediately if pregnancy occurs, if trying to become pregnant, or if breastfeeding. If pregnancy does occur while taking this drug, do not change the dosage without consulting the doctor.
Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SNRIs exposure within the month prior to birth.
Postmarketing reports indicate that some newborns, whose mothers took an SNRI (Serotonin Norepinephrine Reuptake Inhibitor), SSRI (Selective Serotonin Reuptake Inhibitor) or other newer antidepressants during pregnancy, have developed complications at birth requiring prolonged hospitalization, breathing support and tube-feeding. Reported symptoms include: feeding and/or breathing difficulties, seizures, tense or overly relaxed muscles, jitteriness and constant crying.
These symptoms are consistent with either a direct adverse effect of the medication on the baby, or possibly a discontinuation syndrome caused by sudden withdrawal from the drug. These symptoms normally resolve over time. However, if the baby experiences any of these symptoms, contact the doctor as soon as possible.